Quest Diagnostics (DGX) director acquires 6 shares at $189.089
Quest Diagnostics (DGX) director Robert B. Carter reported acquiring 6 shares of common stock on 10/21/2025 at $189.089 per share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Quest Diagnostics (DGX) director Robert B. Carter reported acquiring 6 shares of common stock on 10/21/2025 at $189.089 per share. The shares were obtained through a dividend reinvestment plan eligible for deferred reporting on Form 5 under Rule 16a-6; the transaction was reported early.
After this transaction, Carter beneficially owns 2,698 shares, held directly.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 6 | $189.089 | $1K |
Footnotes (1)
- F1. Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did DGX report?
When did the DGX insider transaction occur?
What was the Form 4 transaction code for DGX?
Was the DGX purchase under a plan?
Who signed the DGX Form 4 and when?
AI-generated analysis. How Rhea-AI works. Not financial advice.